Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to evaluate the intervention effects on blood sugar levels using an AI diet app for personalized meal control and the continuous glucose monitoring system (CGMS) in patients with type 2 diabetes (T2D) The main questions it aims to answer are: 1. Effect of glycemic control on hemoglobin A1c (HbA1c) in T2D patients through continuous glucose monitoring system (CGMS) 2 Effect of blood sugar management intervention using AI diet app ◎ Research method <study arms> - Negative Control group (NC) 20 people (*24 people) checking only hemoglobin A1c (HbA1c) three times (at the beginning of the study, after the 1st 12 weeks, and then after the 2nd 12weeks) - Positive control group (PC) 30 people (*36 people) wearing the CGMS patch for 12 weeks and checking HbA1c three times - Intervention group (IG) 30 people (*36 people) using CGMS patch for diabetes, AI diet app, and checking HbA1c three times (* Actual number of recruits considering dropout) This study's aim is to identify dietary factors for each patient that can affect blood sugar control based on the Continuous Glucose Monitoring System (CGMS) in patients with T2D and to personalize the amount and type of meal intake. It is planned to confirm the effect of blood sugar control intervention through a nutrition counseling coaching system. The sex-stratified random assignment method was used to recruit 20, 30, and 30 study participants in the control group (negative), control group (positive), and intervention group, respectively. Namely, each study group is allocated according to the endocrinology department visiting patients, so the ratio of participants by gender is similarly allocated. The group allocation of subjects uses a double-blind method in which a researcher who is not at all related to research planning, analysis, and interpretation of results assigns subjects according to random sampling numbers.


Clinical Trial Description

This study aims to identify patient-specific dietary factors that can affect blood sugar control based on the continuous glucose monitoring system (CGMS) in T2D patients and to personalize the amount and type of meal intake. [Research method] <study arms> - Negative Control group (NC) 20 people (*24 people) checking only hemoglobin A1c (HbA1c) three times (at the beginning of the study, after the 1st 12 weeks, and then after the 2nd 12weeks) - Positive control group (PC) 30 people (*36 people) wearing the CGMS patch for 12 weeks and checking HbA1c three times - Intervention group (IG) 30 people (*36 people) using CGMS patch for diabetes, AI diet app, and checking HbA1c three times The sex-stratified random assignment method was used to recruit 20, 30, and 30 study participants in the control group (negative), control group (positive), and intervention group, respectively. Namely, each study group is allocated according to the endocrinology department visiting patients, so the ratio of participants by gender is similarly allocated. The group allocation of subjects uses a double-blind method in which a researcher who is not at all related to research planning, analysis, and interpretation of results assigns subjects according to random sampling numbers. [Research design] Parallel design with three arms ◎ Effect evaluation criteria - Based on the time of participation in the intervention study, the effect of CGMS and diet app intervention on blood sugar control in T2D patients will be evaluated by comparing HbA1c at each time point of CGMS intervention and AI diet intervention. - In order to evaluate the difference in blood sugar control according to the use of CGMS, continuous blood sugar records of all CGMS users (PC + IG) for the first 12 weeks will be downloaded daily through the AI diet app and checked to observe irregularities in blood sugar control during the day. In addition, by checking the cumulative data for a week or a month, individual changes in blood sugar will be recorded and evaluated. - To evaluate the blood sugar change according to the intervention using the AI Diet App, IG users' meal records will be downloaded every day, the meal characteristics according to the blood sugar change of CGMS will be identified, and the GL (glycemic index) or GL (glycemic load) will be calculated. - This process includes counseling in which a professional nutritionist sends a text message for individual blood sugar control meals based on an AI diet app and a CGMS app. In addition, the investigators will evaluate the effect of these interventions on glycemic control by measuring HbA1c - The effect of dietary intervention without CGMS for another 12 weeks after the first 12 weeks with CGMS is evaluated in T2D patients by measuring HbA1c before and after implementing only dietary intervention. < Data items to be collected > (1) Surveys three times* - Demographic information: abbreviation of name, gender, date of birth, occupation, education, income, marital status, number of children, female history (menopause, uterine/ovarian removal) - Disease history*: comorbidities, complications, antidiabetic drugs, duration of illness - Nutrition practices*: Number of meals/days, whether or not to eat out, dining out location, main food intake - Lifestyle*: sleep, smoking, alcohol consumption, exercise, physical activity - Diabetes Self-Management Activities*: Execute meal plan, exercise, blood sugar test, diabetes medication, foot care (In the case of *, it is conducted at the beginning, after 12 weeks, and at the end.) - App: Daily meal information - Blood sugar: Continuous blood sugar information through CGMS patch <Consideration of safety for research participants> 1. Basic procedures to secure research ethics This study complies with the Declaration of Helsinki and ICH-GCP and will be conducted after IRB approval. 2. Personal information plan for research subjects Personal information that can be collected in this study includes name, initials, sex, year of birth, contact information, and account number. Personal information is used for research through deletion or anonymization and is only accessible to authorized researchers. Individual identification through the use of the data built up is impossible, and the information obtained from the research will not be used for purposes other than confirming or researching the occurrence of diseases in the future. <Research participant incentives> Negative control group: 40,000 won for clinical participation Positive control group: 60,000 won for clinical participation Intervention group: 100,000 won for clinical participation ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06089655
Study type Interventional
Source KangWon National University Hospital
Contact Eunhee Cho, MD
Phone +82-33-258-9167
Email ehcho@kangwon.ac.kr
Status Recruiting
Phase N/A
Start date September 1, 2023
Completion date May 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A